Stocks · News reference

Verrica Pharmaceuticals Announces Completed Enrollment In COVE-2 Pivotal Phase 3 Trial Of YCANTH For Common Warts; Says Topline Data Expected In Q1 2027

Aug 27, 2026, 12:04 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 14, 2026, 9:37 AMBenzinga Insights
Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial
VRCA
SEC EDGARAug 6, 2026, 8:34 PMSEC EDGAR
8-K filing — Verrica Pharmaceuticals Inc. (VRCA)
Filed: 2026-08-06 AccNo: 0001193125-26-338273 Size: 304 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
VRCA
BenzingaAug 6, 2026, 8:08 PMBenzinga Newsdesk
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 292 percent decrease over earnings of $0.25 per
VRCA